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ABSTRACT 
 
Antibodies are central proteins of the humoral immune response of vertebrate species. 
The function of antibodies is based on their capability to specifically recognize the 
pathogenic antigens. The high diversity and specificity of antibodies has been widely 
applied to diagnostic, therapeutic, and research applications. In this study, the 
molecular basis for the function of an allergen binding IgE Fab fragment and two 
hapten (small molecule) binding IgG Fab fragments was examined by determining 
crystal structures of the antibodies in complex with their target antigens.  
 
The crystal structure of a recombinant IgE Fab fragment in complex with a bovine 
beta-lactoglobulin (BLG) allergen was determined at 2.8 Å resolution. BLG, from the 
lipocalin protein family, is one of the major allergens of cow´s milk and causes food 
allergy, especially among infants and young children. The solved structure revealed 
that two IgE molecules were bound to a dimeric allergen. The IgE binding site is 
located on the planar surface of the BLG allergen and is mainly composed of β-strands. 
Therefore, the IgE epitope of BLG differs substantially from the common IgG 
epitopes. This complex structure provided the first insight into IgE antibody-allergen 
interactions at the molecular level. The findings are expected to be useful in the 
development of novel approaches to the treatment of allergy. 
 
Steroid hormones are one class of important analytes for which antibodies have been 
developed during recent years. In this study, the crystal structure of the anti-
testosterone Fab fragment 5F2 from a naïve human antibody library was solved at 1.5 
Å resolution. The crystal was pseudomerohedrally twinned, which complicated the 
structure determination. In the solved structure, the testosterone was buried in a 
hydrophobic binding pocket and the heavy chain of the antibody was mainly 
interacting with the hapten molecule. The testosterone binding site of the 5F2 Fab with 
a high abundance of aromatic amino acid residues showed clear similarity with steroid 
binding antibodies that have been isolated from non-human sources. The solved 
structure is expected to facilitate the design of specific modifications that could 
enhance the binding properties of the antibody. 
 
Preparations of the cannabis plant, such as hashish and marijuana, are widely used as 
illicit drugs in the world. The main psychoactive compound of the cannabis plant is 
tetrahydrocannabinol (∆9-THC). The T3 Fab fragment, generated for the detection of 
THC in biological samples, was crystallized in the absence and the presence of THC 
and the crystal structures were solved at 1.9 Å and 2.0 Å resolution, respectively. The 
T3 Fab binds THC into a narrow pocket between the variable domains of the antibody. 
In contrast to the 5F2 Fab fragment, the T3 Fab binds the hydrophobic molecule 
mainly through aliphatic amino acid residues. The solved structure is the first three-
dimensional structure of a protein complexed with a psychoactive cannabinoid. 
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ABBREVIATIONS 
 
 
BLG  bovine beta-lactoglobulin 
CDR complementarity determining region 
ESI-FTICR electrospray ionization Fourier transform ion cyclotron resonance 
ESRF European Synchrotron Radiation Facility 
Fab antigen binding fragment of an antibody 
Fab 5F2 testosterone binding IgG Fab fragment 
Fab D1 beta-lactoglobulin binding IgE Fab fragment 
Fab T3 tetrahydrocannabinol binding IgG Fab fragment 
Fc crystallizable (constant) fragment of an antibody 
IgE immunoglobulin E 
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kDa kilodalton = 103 g/mol 
NCS non-crystallographic symmetry 
PDB Protein Data Bank 
PEG polyethylene glycol 
rmsd root-mean-square deviation 
scFv single-chain variable fragment 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TES testosterone 
THC Δ9-tetrahydrocannabinol 
Å  ångström = 1 × 10-10 m 
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1 INTRODUCTION 
 
The immune system of vertebrates has evolved to protect the host from pathogens, 
such as bacteria and viruses. Immunity can be divided into innate and adaptive 
immunity. The innate immunity, which provides the first line defence against 
infections, is composed of elements that are the same in all members of a species. 
Unlike the innate immunity, the adaptive immunity is highly specific, resulting from a 
contact with a foreign substance (antigen). Lymphocytes are the type of white blood 
cells that have a central role in the adaptive immunity. T lymphocytes, or T cells, are 
involved in the cell-mediated immunity, whereas the humoral immunity is mediated by 
B lymphocytes (B cells). The principal function of B cells is to produce soluble 
glycoproteins, known as antibodies. Antibodies are capable of specifically binding to 
the antigen molecules, thus facilitating their elimination by other components of the 
immune system.  
 
Two scientists, G.M. Edelman and R.R. Porter, shared the Nobel prize for Medicine 
1972, awarded for their discoveries concerning the chemical structure of antibodies. A 
year later, the three-dimensional structures of two proteins produced by myeloma 
tumor, the immunoglobulin light chain dimer1 (Bence-Jones protein) and the Fab 
fragment of a human immunoglobulin,2 were characterized by X-ray crystallography. 
Within the following decades, the structures of hundreds of different antibodies or 
fragments of antibodies, which recognize a wide variety of antigens from small 
molecules to large proteins, have been determined experimentally. Although the basic 
structure of all antibodies is highly similar, each antibody has a unique binding 
specificity and affinity to the target antigen. Specific recognition originates at the 
molecular level and is achieved through non-covalent interactions between an antibody 
and an antigen. The structural characterization of antibody-antigen complexes is 
essential for understanding the recognition mechanism of an antibody. The knowledge 
of an antibody structure and its function is also a remarkable benefit for protein 
engineering. 
 
1.1 THE GENERAL STRUCTURE OF ANTIBODIES 
 
The basic structure of an immunoglobulin molecule consists of two light chains and 
two heavy chains connected together by disulfide bonds. The light and heavy chains of 
an antibody are folded into domains, each containing about 110 amino acid residues. 
The antiparallel β-strands of a domain arrange in two layers of β-sheets, which pack 
closely against each other. This characteristic beta-sandwich structure has also been 
found in other proteins and is commonly known as the immunoglobulin fold (Figure 
1).  
 
The amino acid sequence variation in antibodies is located in the amino-terminal 
variable domains of both the heavy chains and the light chains. Meanwhile, the 
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diversity of the remaining constant domains is more limited among the antibodies that 
belong to the same class. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The immunoglobulin fold. The constant domain (a) consists of seven antiparallel β-
strands. The variable domain (b) contains two additional strands, 3b and 3c. CDR-loops that 
connect β-strands 2-3, 3b-3c, and 6-7 are shown in orange.  
 
The most diverse regions of a variable domain occur in three loops that connect the 
adjacent β-strands. An antibody binds an antigen mainly through these 
complementarity determining regions (CDRs), which are clustered together in the 
structure of a folded antibody (Figure 1b). The enormous diversity and binding 
specificity of antibodies is mainly reached by varying the amino acid composition and 
the length of the CDR-loops.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. a) The basic structure of an immunoglobulin G (IgG, PDB code 1IGT3). The 
molecular weight of an IgG is around 150 kDa and the molecule consists of two Fab fragments 
(Mw ∼50 kDa) and one Fc fragment. The light chains of the antibody are shown in gray and the 
heavy chains are in green. b) Schematic structures of antibodies of five main classes. Disulfide 
bonds are shown as black thin lines.  
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The controlled cleavage by a proteolytic enzyme papain degrades an intact 
immunoglobulin into fragments. The antigen binding fragment (Fab) contains the 
entire light chain (VL, CL) combined with the variable VH and constant CH1 domains 
of the heavy chain, whereas the Fc fragment involves the rest of the constant domains 
of the heavy chain. While the specificity of an antibody is primarily centered in the 
CDR loops of the variable domains, the constant domains of the heavy chain mediate 
the effector functions. Antibodies are divided into classes based on the properties of the 
heavy chain (Figure 2b). Five antibody classes (IgA, IgD, IgE, IgG and IgM) have 
different heavy chain isotypes, which define the biological activity of the antibody. 
One of the two light chain types (kappa or lambda) can associate with each of these 
heavy chain isotypes. No functional differences have been observed in the light chain 
classes. 
 
1.2 IGE-MEDIATED (TYPE 1) HYPERSENSITIVITY 
 
Allergies are caused by an inappropriate immune response against non-pathogenic 
substances, known as allergens. In the developed countries, asthma and other allergic 
disorders such as hay fever, eczema and even life-threatening anaphylaxis, have 
become a serious problem for public health.4 The type 1 allergy initiates the production 
of allergen-specific class E (IgE) antibodies on B cells. IgE antibodies secreted by B 
cells are capable of sensitizing blood basophiles and tissue mast cells by binding to 
high-affinity FcεRI receptors located on their surface. The simultaneous binding of two 
membrane-bound IgE antibodies to an allergen molecule induces the cross-linking of 
receptors, which triggers the cells to release histamine and other biological mediators, 
thus causing an allergic inflammation (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Degranulation of a mast cell. 
 
 
Allergens are almost exclusively proteins that are present in the common substances of 
daily life, such as food products, tree and grass pollens and animal dander. The 
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biochemical and the structural characterization of a large number of allergenic proteins 
have not revealed any common feature that could explain their capacity to induce IgE 
production.5 However, evidence that the structural properties of proteins may also have 
some effect on allergies has been obtained in recent years: the structural classification 
of allergens has revealed that only a limited number of protein families contain 
allergens.6,7 In addition, certain allergen-specific IgG antibodies bind allergens with a 
lower affinity than corresponding IgE antibodies8 and some allergens are weak 
immunogens that do not stimulate IgG production very well.9,10 These results suggest 
that allergens may have some unique structural features, which are not easily available 
for IgG antibodies but are, in contrast, recognized by IgE antibodies.  
 
An allergen-specific IgE binds to an immunologically active region of an allergen, i.e. 
a B cell epitope. Since the allergic reactions arise from the interactions between the IgE 
and allergen, the identification of B cell epitopes has been the major interest in allergy 
research. Although B cell epitopes have been sought by several methods (e.g. epitope 
mapping and site-directed mutagenesis), the rational method to determine a complete B 
cell epitope is to solve the crystal structure of an allergen-specific IgE in complex with 
the allergen.11 However, the low abundance of IgE in the serum of even the most 
severely allergic patients and the failure to produce monoclonal IgE antibodies by 
conventional hybridoma technology have been the major obstacles for accessing IgE 
for structural studies. 
 
1.3 ANTIBODIES IN DIAGNOSTICS AND THERAPY 
 
The specific recognition of antibodies has been widely utilized in immunodiagnostic 
and therapeutic applications. A number of important analytes, including the steroid 
hormones and drugs, are small organic molecules that contain only a few functional 
groups and exist at a low concentration in biological samples. The selective and 
specific recognition of the particular analyte may be achieved by using high-affinity 
antibodies. The production of antibodies specific for small molecules (haptens) 
requires that a hapten is conjugated to a carrier protein, because small molecules 
cannot induce the immune response by themselves. Advances in biotechnology, 
especially the availability of large antibody phage libraries, have allowed the 
generation of antibodies against an almost unlimited variety of molecules.12-15 Human 
phage display libraries have also enabled the selection of human antibodies for 
immunotherapy.15-17  
 
Immunoassays that are based on specific antibody-antigen interactions are commonly 
used in diagnostics. The sensitivity of traditional immunoassays has been further 
improved by developing non-competitive immunoassays, where two antibodies bind 
the different epitopes of the target analyte. Non-competitive immunoassays have also 
been generated for the detection of several low molecular weight analytes.18-21 In these 
novel assays, the limitation caused by the size of the analyte is overcome by the use of 
anti-immunocomplex (anti-IC) antibodies that specifically recognize the complex 
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formed between the primary antibody and the analyte. The binding properties of 
antibodies can be modified in order to improve the affinity and the specificity towards 
the analyte or to decrease the cross-reactivity with closely related molecules, thus 
improving the accuracy and the reliability of immunoassays.  
 
The development of therapeutic antibodies is a continuously growing area in the 
pharmaceutical industry.22 So far, therapeutic monoclonal antibodies are available for 
the treatment of several diseases, e.g. virus infections and cancer. In human 
immunotherapy, the use of murine antibodies can cause side effects and evoke an 
immune response, which reduces the efficiency of the therapy. Therefore, the 
humanized antibodies and the fully human antibodies isolated from gene libraries are 
of particular interest for the development of new therapeutic applications.  
 
2  AIMS OF THE STUDY  
 
The general purpose of this study was to determine the crystal structures of three 
different antibody-antigen immunocomplexes by X-ray crystallography, in order to 
understand the relationship between the structure and the function of the antibodies. 
The specific aims were as follows: 
 
1. To crystallize and solve the structure of a recombinant IgE Fab fragment in complex 
with the bovine beta-lactoglobulin, one of the major allergens of cow´s milk. Before 
this study, the structures of IgE antibody-allergen complexes had not been determined. 
The complex structure was expected to yield new information about the IgE-allergen 
interactions that could extend the knowledge of the molecular mechanism of allergies 
and might also be useful in the development of novel applications for the treatment of 
allergic disorders.  
 
2. To crystallize and determine the three-dimensional structure of an anti-testosterone 
Fab fragment 5F2 in complex with its specific hapten. 5F2 Fab was isolated from a 
naïve human phage display library, in contrast to previously characterized mouse anti-
testosterone Fab fragments. By solving the structure, it would be possible to compare 
the mouse and human antibodies that bind an identical molecule. Knowledge of 5F2 
Fab-testosterone interactions also enables the modification of selected amino acids that 
could improve the binding specificity and affinity of the antibody. 
 
3. To crystallize and determine the structure of an anti-tetrahydrocannabinol Fab 
fragment T3 in free form and in complex with Δ9-tetrahydrocannabinol (THC), the 
major psychoactive compound of Cannabis sativa. The three-dimensional structure of 
the T3 Fab in complex with THC would provide the first insight into the molecular 
interactions between a protein and the Δ9-tetrahydrocannabinol. Because the T3 Fab 
was generated for the detection of THC in biological samples, the information on T3 
Fab-THC interactions could also be useful for designing specific mutations, so that the 
antibody fits the target application better.  
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3  MATERIALS AND METHODS 
 
All materials and methods of the study are described in detail in the original 
publications I-V. A brief summary is presented below. 
 
Fab fragments were isolated, produced and purified at the VTT Technical Research 
Centre of Finland. The VL and VH regions of a D1 antibody were isolated from IgE 
ScFv phage display library, constructed from lymphocytes of a milk allergic patient. 
The isolated IgE scFv fragment was converted to a Fab fragment by cloning the CH1 
and CL regions from a human IgG1 heavy chain and kappa light chain to variable 
domains of D1 antibody. The genes encoding the D1 Fab fragment were cloned into 
the bacterial expression vector (pKKtac)23 and the Fab fragment was produced by high-
cell density fermentation of E. coli strain RV308. The expressed Fab fragment with the 
C-terminal hexahistidine tag was purified by immobilized metal ion affinity 
chromatography. The purity and homogeneity of the protein solution was checked by 
non-reducing SDS-PAGE and ESI-FTICR mass spectrometry. D1 Fab binds native 
BLG with nanomolar affinity (Kd 1.3 × 10-9 M) and partially inhibits serum IgE to bind 
BLG.24 BLG (Mw ∼18.3 kDa) from bovine milk is a commercially available protein 
ordered from Sigma Aldrich.  
 
The small molecule binding Fab fragments 5F2 and T3 were produced and purified by 
a procedure similar to that described for the D1 Fab fragment. The anti-testosterone 
Fab 5F2 was isolated from a naïve human phage display library. 5F2 Fab has the IgG 
heavy chain combined with the type lambda light chain. The binding affinity of 5F2 
Fab to testosterone is ~900 nM, determined by competitive ELISA. The anti-
tetrahydrocannabinol Fab T3 was isolated from a phage display library, constructed 
from mice immunized with a THC-BSA conjugate. T3 is a Fab fragment of IgG 
antibody with the kappa light chain. The binding affinity of T3 Fab to THC is ∼500 
nM. Both testosterone and Δ9-THC were purchased from Sigma Aldrich. THC was 
used in crystallization with the permission of the Finnish Medicines Agency. 
 
All Fab fragments were crystallized by the hanging-drop vapor-diffusion method at 
room temperature using PEG3350 as a precipitant. X-ray diffraction data sets were 
collected at cryo-temperature (100 K) using synchrotron radiation at the ESRF, 
Grenoble. The diffraction images were processed by using XDS and scaled and merged 
with XSCALE.25 Antibody structures were solved by the molecular replacement 
method, using previously determined Fab structures as search models. The principal 
selection criteria for the search models were their high sequence identity with the target 
protein. The rotation and the translation functions were determined separately for the 
variable domains and the constant domains of an antibody. The protein models were 
built up by several refinement cycles and manual fitting with the program O.26 The 
topology files for hapten molecules were created with PRODGR.27 The solvent 
accessible surfaces were calculated with AreaImol from the CCP4 program package28 
and the program NCONT (CCP4) was used to search the contacts between the 
antibody and the antigen. The elbow angles of the Fab fragments were determined with 
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RBOW.29 The stereochemical quality of the antibody structures was confirmed with the 
ADIT30 validation server.  
 
4 RESULTS AND DISCUSSION 
 
4.1 PROTEIN CRYSTALLOGRAPHY 
 
4.1.1 CRYSTALLIZATIONI, III, IV, V 
 
The conditions that favor the nucleation process are not generally optimal for the 
controlled growth of protein crystals. Therefore, the crystals obtained from the initial 
crystallization experiment are not usually of sufficient size and quality for X-ray 
analysis. The careful optimization of the crystallization conditions or the use of 
crystallization additives may be crucial to the growth of high-quality crystals. The 
spontaneous nucleation step can also be bypassed by introducing nuclei into a 
crystallization drop at a lower level of supersaturation. In the commonly used streak-
seeding method, the transferred nuclei are obtained from previously grown protein 
crystals. If pre-existing crystals are not available as a source of nuclei, the introduction 
of heterogeneous material into a crystallization droplet may promote the nucleation of 
a protein. Besides other optimization methods, a new class of heterogeneous nucleant, 
polystyrene nanospheres, was tested in the crystallization of the 5F2 and T3 Fab 
fragments. Polystyrene nanospheres with different particle diameters are commercially 
available calibration standards for electron and atomic force microscopy. 
 
The D1 Fab fragment precipitated when the concentration of the protein solution was 
increased. Therefore, a D1 Fab concentration of 1.4 mg/ml was used in the 
crystallization experiments. The lyophilized BLG was dissolved into pure water to a 
concentration of 2 mg/ml. D1 Fab-BLG complex crystals were obtained using a 14% 
(w/v) PEG3350, 0.1 M BTP solution at pH 5.0. Initial crystals grew as clusters of thin 
needles from which single crystals were not possible to separate. The addition of a n-
dodecyl-β-D-maltoside detergent solution to crystallization droplets proved to be 
essential for the growth of three-dimensional crystals. Microcrystal with approximate 
dimensions of 0.07 × 0.05 × 0.05 mm appeared in the crystallization droplets within a 
week (Figure 4a).  
 
Anti-testosterone Fab 5F2 was co-crystallized with the hapten using a 12% (w/v) 
PEG3350, 0.1 M sodium citrate at pH 4.7 as a precipitant solution. The 5F2 Fab 
concentration was ~8 mg/ml and an 8-fold excess of testosterone was used in 
crystallization. Single 5F2 Fab crystals suitable for X-ray analysis were obtained by 
combining the streak-seeding method with the polystyrene nanospheres. Crystal 
dimensions were approximately 0.2 × 0.1 × 0.1 mm (Figure 4b). Attempts to crystallize 
5F2 Fab without the testosterone were unsuccessful.  
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Anti-tetrahydrocannabinol Fab fragment T3 was crystallized both in the absence and 
the presence of THC. The concentration of T3 Fab in crystallization experiments was ~ 
18 mg/ml. The optimal precipitant solution for the uncomplexed T3 Fab was found to 
be a 14 % (w/v) PEG3350, 0.1 M sodium citrate at pH 5.2. Crystals grew up to 
dimensions of 0.6 × 0.3 × 0.2 mm within a week (Figure 4c). In co-crystallization 
experiments, a 10-fold excess of hapten was used. The T3 Fab-THC complex was 
crystallized with a 12% (w/v) PEG3350, 0.1 M sodium HEPES solution at pH 7.5. As 
the initial complex crystals were spherical in shape, a nanosphere solution and the 
streak-seeding method were used to improve the quality of the crystals. Single crystals 
with dimensions of 0.1 × 0.1 × 0.05 mm were obtained within 2-3 days after the 
seeding (Figure 4d).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Protein crystals: a) D1/BLG b) 5F2/TES c) T3 d) T3/THC. The black bars indicate 
the estimated crystal sizes. 
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4.1.2 DATA COLLECTION AND PROCESSINGI, IV, V 
 
Summary of the data collection and processing statistics are presented in Table 1. 
 
Table 1. Data collection and processing statistics. Values in parentheses are for the 
highest resolution shell. 
 
  D1/BLG 5F2/TES T3 T3/THC 
     
Beamline ID29 ID29 ID14-4 ID14-4 
Space group P212121 P1 P43212 P43212 
Unit cell parameters     
 a, b, c (Å) 67.0, 100.6, 168.1 66.8, 67.1, 67.1 121.4, 121.4, 73.5 122.8, 122.8, 73.3 
α, β, γ (°) a = b = c = 90 81.3, 69.3, 69.3 a = b = c = 90 a = b = c = 90 
Resolution (Å) 2.8 (2.9-2.8) 1.5 (1.6 -1.5) 1.9 (2.0-1.9) 2.0 (2.1-2.0) 
No. of reflections 207474 299821 390342 272030 
Unique reflections 28674 151891 43799 38070 
Robs (%) 15.9 (55.2) 3.3 (32.1) 5.4 (38.6) 3.9 (44.5) 
Rmeas (%) 17.2 (59.4) 4.7 (45.3) 5.7 (41.6) 4.2 (47.9) 
Average I/σ 13.1 (3.5) 14.0 (2.5) 22.7 (5.1) 28.4 (4.5) 
Completeness (%) 99.8 (100) 93.1 (91.0) 100 (100) 99.2 (99.9) 
          
 
 
4.1.3 STRUCTURE DETERMINATION AND REFINEMENTII, IV, V 
 
The D1 Fab-BLG complex structure was solved using the Fab fragment of the human 
IgG antibody specific for the transmembrane protein gp41 of the HIV-virus31 (PBD 
code 1DFB) and a BLG monomer32 (1B8E) as search models. Molecular replacement 
was carried out with MolRep33 and the complex structure was refined with the program 
CNS.34 Because of the low number of unique reflections, NCS restraints were used in 
refinement.  
 
The search model for the 5F2 Fab was the VLA-1 integrin 1 domain binding Fab 
fragment of a humanized AQC2 antibody35 (PDB 1MHP). The structure refinement 
was carried out with PHENIX.36 Coordinates for the testosterone were obtained from a 
previously determined Fab-testosterone structure.37 
 
The structure of the THC binding Fab fragment T3 was solved using the Fab fragment 
of a catalytic antibody 6D938 (2DQT) as a search model. The long CDR-loops of the 
search model were deleted before the molecular replacement was carried out. The 
molecular replacement was performed with Phaser39 and the structure was refined with 
PHENIX. The initial coordinates for hapten were obtained from a modelled THC 
structure. The refinement statistics are presented in Table 2. 
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Table 2. Refinement statistics and validation.  
 
  D1/BLG 5F2/TES T3 T3/THC 
     
Rwork (%)  24.6 17.9 21.4 21.4 
Rfree (%) 29.1 20.8 24.3 26.1 
No. of atoms  9136 7532 3547 3566 
Protein 9066 6571 3287 3302 
Hapten - 42 - 24 
Additive 70 - - - 
Water - 919 260 240 
Average B (Å2) 27.4 20.1 34.2 39.2 
Rms deviations     
Bond lengths (Å) 0.009 0.013 0.013 0.012 
Bond angles (°) 1.2 1.7 1.5 1.6 
PDB code 2R56 3KDM 3LS5 3LS4 
          
 
 
4.1.4 NANOSPHERES IN THE CRYSTALLIZATION OF FAB 
FRAGMENTSIII  
 
The initial 5F2 Fab fragment crystals grew in clusters. Although single crystals were 
obtained by the streak-seeding method, the crystallization droplets required a long 
equilibration time (2-3 weeks) before the seeding. When nanospheres (50 nm in 
diameter, 1:1 dilution to water) were added to droplets prior to seeding, substantially 
shorter equilibration times could be used: single crystals appeared in droplets, which 
were allowed to equilibrate for only 24 hours. The growing of diffraction-quality 
crystals in the presence of nanospheres was still dependent on the use of seeding. 
Otherwise, the crystals grew in clusters in nanosphere droplets. The combination of the 
polystyrene nanospheres with the streak-seeding method also proved to be an efficient 
technique for producing T3 Fab-THC crystals for structure determination. The use of 
nanospheres and seeding improved the quality of complex crystals. By contrast, in 
similar conditions, the traditional streak-seeding method yielded crystals that were of 
poor quality, visually. The effect of nanospheres on the crystallization of complexed 
T3 Fab without seeding was not examined. 
 
Although polystyrene nanospheres were observed improving the quality of the protein 
crystals and affecting the equilibration time of crystallization droplets, the mechanism 
by which nanospheres function is not clear. It is possible that nanospheres act as a 
heterogeneous nucleant, providing a regular surface onto which protein molecules can 
assemble. The alternative explanation is that nanospheres take up space in solution, in 
which case the protein molecules can cluster closer together and form crystal nuclei. 
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4.1.5 TWINNING IN A 5F2 FAB CRYSTALIV 
 
Pseudomerohedral twinning may occur in a protein crystal as a consequence of unusual 
unit-cell geometry. In a pseudomerohedrally twinned crystal, the metric symmetry of 
the lattice is higher than the Laue symmetry of the crystal.40,41 A triclinic crystal can be 
pseudomerohedrally twinned if the two axes and two angles of the cell appear to be 
almost equal. This kind of twinning where a triclinic crystal mimics a monoclinic one 
has been previously noticed in an RNA fragment crystal.42 The structure of 5F2 Fab 
was initially solved in space group C2. Twinning was detected when the electron 
density maps revealed two alternative positions for the polypeptide chain near the 
crystallographic twofold axis (Figure 5a). The data were indexed in space group P1 and 
the twin law -h, -l, -k was introduced into the structure refinement. The twin refinement 
decreased both the crystallographic R-factors and improved the quality of the electron 
density maps (Figure 5b).  
 
 
 
 
 
 
 
 
 
 
Figure 5. A portion of electron density maps. a) Electron density near the crystallographic 
twofold axis when the structure was refined in space group C2. b) The same area after the twin 
refinement in space group P1. The 2Fo-Fc map (blue) is contoured at 1.5 σ and the Fo-Fc map 
(green) at 2.5 σ.  
 
 
4.2 THE IGE FAB-ALLERGEN COMPLEX D1/BLGII 
 
The three-dimensional structure of the IgE Fab-allergen complex D1/BLG was solved 
at 2.8 Å resolution. The asymmetric unit contained two D1 Fab fragments bound to a 
dimeric allergen (Figure 6), representing the entire immunocomplex. The structure of 
the allergen in complex corresponds to a previously determined BLG structure.43 BLG 
monomers are folded into a native β-barrel structure, where eight antiparallel β-strands 
form the core of the protein. The structure is stabilized with two intramolecular 
disulfide bonds formed between the cysteine residues of the BLG. BLG is known to 
bind a number of small molecules, such as fatty acids44,45 and retinol,46 inside the 
hydrophobic binding cavity. The electron density found in the binding site of both 
BLG monomers was interpreted as a detergent molecule, used to improve the quality of 
the complex crystals. The hydrophilic maltoside moiety of the detergent is located 
outside the binding cavity, but is far away from the bound IgE antibody. The location 
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of a non-crystallographic 2-fold symmetry axis between the BLG monomers was also 
equal to that observed in a native BLG dimer.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The overall structure of the IgE antibody-allergen immunocomplex. The figure shows 
how two D1 Fab fragments (light chain in blue, heavy chain in green) bind the dimeric beta-
lactoglobulin allergen. Allergen monomers are shown in light and dark gray and the detergent 
molecules are in yellow. 
 
 
The variable domains of the D1 Fab fragment follow the typical immunoglobulin fold 
described for variable domains of common IgG antibodies. All three CDR-loops of the 
light chain and the CDR-H1 and CDR-H2 loops of the heavy chain belong to known 
canonical classes of immunoglobulins.47 The CDR-H3 loop with the bulged 
conformation in the torso region48 is a relatively long loop with 17 amino acid residues. 
The H3-loop is folded towards the other CDR-loops, creating the flat binding site of 
the antibody. The calculated elbow angles of the D1 antibodies are 141° and 150°, 
which are common values for Fab fragments containing a kappa light chain.29 The total 
interface area of the antibody-allergen complex is large (1825 Å2), but does not 
substantially deviate from the average interface area (1680 Å2) of protein antigen-
antibody complexes.49 
 
 
4.2.1 THE IGE BINDING SITE OF BLG 
 
The D1 Fab recognizes a conformational epitope, which is located on a planar surface 
of the BLG allergen (Figure 7a). The IgE binding site is similar in both BLG 
monomers and the epitope area does not extend to the surface of the second monomer 
or to the dimer interface. The complete IgE epitope of native BLG consists of six short 
fragments of the polypeptide chain, which are mainly located in the secondary 
structure elements of the protein (Figure 7b). In the complex structure, 15 amino acid 
residues of BLG (9 % in total) are in contact with an antibody and 27 amino acid 
residues (17% in total) are at least partially buried under the bound antibody. The 
buried area is 890 Å2, which covers 10% of the surface of the BLG monomer. The 
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major part of the epitope consists of the four adjacent β-strands: segment 1 (Trp19-
Tyr20), segment 2 (Val43-Lys47), segment 3 (Leu57-Gln59) and segment 4 (Cys66-
Gln68). In addition, the loop between the eighth β-strand of the BLG and the following 
α-helix (segment 5, Pro126-Glu127) and the short C-terminal helix (segment 6, 
Thr154-Glu157) form the IgE binding site of BLG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The IgE epitope of the beta-lactoglobulin.II a) Location of two monovalent epitopes 
on the surface of a dimeric allergen. b) The complete IgE epitope of the BLG consists of six 
short fragments, numbered from 1 to 6. The residues that are in contact with the D1 antibody 
are colored red and the residues that are buried upon the complex formation are colored in 
orange. 
 
All six CDR-loops of the D1 Fab participate in allergen binding (Figure 8a). In total, 
13 hydrogen bonds and 2 salt bridges are formed between the antibody and the 
allergen. Only two of the interacting amino acids are aromatic, which is unusual.49,50 
The heavy chain of D1 Fab dominates the interactions between the antibody and 
allergen, as commonly observed in determined antibody-antigen complexes. The light 
chain of D1 Fab is responsible for binding three adjacent β-strands of BLG (segments 
2, 3 and 4): CDR-L1 (Ser30L, Ser31L and Arg32L) interacts with segments 3 and 4 
and CDR-L2 (Tyr49L, Ala50L and Ser52L) interacts with segments 2, 3 and 4. CDR-
L3 has a minor role in binding the β-strand region of the BLG. One hydrogen bond is 
formed between the Tyr91L from CDR-L3 and the Gln68 from segment 4. Besides the 
named interactions, His92L is within 4.0 Å of Glu66 located before segment 4 and 
may, thus, raise the contribution of the CDR-L3 to allergen binding.  
 
His31H from CDR-H1 interacts with Pro126 and Glu127 from the loop region of the 
BLG (segment 5). CDR-H2 takes part in binding the short C-terminal helix (segment 
6) through two serine residues, Ser52H and Ser54H. CDR-H3 is located in the middle 
of the variable domains and has a central role in antigen binding. In complex structure, 
Arg101H on the tip of the CDR-H3 loop reaches a small cavity formed between the C-
terminal helix and β-strands A and B of BLG, interacting with residues from segment 1 
and 2. Val102H from CDR-H3 region contributes to allergen binding by recognizing 
Tyr20 from segment 1 and Pro126 from segment 5.  
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Figure 8. Contacts between the D1 Fab and the BLG.II a) Location of the CDR-regions on the 
surface of the D1 Fab. b) The interacting amino acid residues of the D1 Fab. 
 
 
4.2.2 THE DIMERIC NATURE OF THE ALLERGEN 
 
Besides an allergen being capable of inducing specific IgE production, it should also 
contain multiple IgE binding sites for an effective cross-linking of two IgE-FceRI 
complexes. This requirement means that at least two IgE antibodies with different 
binding specificities should occur on the surface of basophiles or mast cells and these 
antibodies should bind an allergen simultaneously. When an allergen is a small protein, 
the surface area is limited and the requirement of various epitopes is hard to fulfill. The 
alternative way for an allergen to cross-link the receptors is oligomerization. If an 
allergen is able to form a dimer or larger oligomers, one epitope in each allergen 
monomer is sufficient to cause the cross-linking of receptors. This may increase the 
protein´s capability to operate as an allergen.  
 
The oligomerization state of beta-lactoglobulin is known to be dependent on several 
parameters, such as pH, temperature and protein concentration.51,52 In physiological 
conditions, BLG predominantly exists as a dimer. The minimum distance of receptor-
bound IgE molecules linked by a natural allergen has not been reported. Based on the 
studies conducted on artificial antigens, the distance between the cross-linked IgE 
molecules has been estimated to be 5-24 nm (50-240 Å).53,54 The length of the dimeric 
BLG is around 7 nm, and the distance between the bound D1 Fab molecules in the 
complex structure is approximately 5 nm. The relative position of the monovalent IgE-
epitopes of BLG and the distance between the bound D1/IgE molecules thus enables 
the cross-linking of FceRI receptors. Although several allergens have been observed to 
appear as dimers or larger oligomers in nature, including the animal allergens Can f 1 
and Can f 2 from dog,55 Equ c 156 from horse and Fel d 157 from cat, timothy grass 
pollen allergens Phl p 158 and Phl p 759, and food allergens Ara h 160,61 and Ara h 262 
from peanut, the significance of oligomerization for protein allergenicity has been 
insufficiently examined. However, Schöll et al. have recently shown that the dimeric, 
not the monomeric, form of the birch pollen allergen Bet v 1 was able to cross-link IgE 
antibodies in mice.63  
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4.2.3 COMPARISON OF IGE AND IGG EPITOPES  
 
The major part of the IgE binding site of BLG is composed of a planar β-sheet region. 
A comparison with over 80 different antibody-antigen complexes showed that the IgE 
epitope of BLG is unique among the common IgG epitopes of protein antigens. The 
typical IgG epitope is located on the protruding or concave surface of an antigen. An 
analysis of IgG epitopes also revealed that half of the epitopes were formed by loops 
alone, and the other half contained both loops and secondary structure elements. 
Recently determined IgG-allergen structures exemplify the common IgG-type binding: 
in birch pollen allergen Bet v 164 the epitope is formed by a β-hairpin; in bee venom 
hyaluronidase Api m 2,65 the epitope is a helix-turn-helix motif; and in German 
cockroach allergen Bla g 2,66 the epitope is composed of loops. The recently solved 
structure of the complex between the timothy grass pollen allergen Phl p 2 and human 
IgE-derived Fab huMab267 is in agreement with the hypothesis that IgE antibodies 
prefer different binding sites than IgG antibodies. In this complex, the IgE epitope of 
the Phl p 2 is located on the planar four-stranded β-sheet region on the surface of the 
allergen. Similarly, with D1 antibody, the Phl p 2-specific IgE Fab also binds the 
allergen with high affinity (Kd 1.1 × 10-10 M).  
 
 
 
 
 
 
 
 
 
Figure 9. A comparison between IgE and IgG epitopes. a) BLG-IgE/FabII b) Phl p 2-IgE/Fab67 
c) Bet v 1-IgG/Fab64 d) Api m 2-IgG/Fab65 e) Bla g 2-IgG/Fab.66  
 
 
 
4.2.4 SEQUENCE SIMILARITY BETWEEN IGE ANTIBODIES 
 
Both the BLG-specific IgE Fab fragment D1 and the Phl p 2-specific IgE fragment 
huMab2 were selected from the phage display libraries constructed from lymphocytes 
of allergic patients. The pairing of the heavy chain and the light chain is not, therefore, 
necessarily the same as in the complete IgE molecules that naturally occur in patient 
serum. However, both of these IgE Fab fragments inhibit the serum IgE from binding 
with the cognate allergen. So far only a few sequences of allergen-specific IgE 
antibodies have been characterized.68-71 The heavy chain amino acid sequences of these 
IgE antibodies vary substantially, whereas some of the light chains share a high 
sequence homology, especially the CDR-L1 and CDR-L2 loops. The light chain 
similarity occurs also between D1 Fab and huMab2. Although the light chain of D1 
Fab recognizes the β-sheet region on BLG, the light chain of the Phl p 2-specific 
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antibody is not in contact with the planar β-sheet region of the allergen. Because only 
two structures of IgE-allergen complexes have been solved by X-ray 
crystallography,II,67 the connection between the light chain sequence homology and the 
nature of the B cell epitope is difficult to evaluate. At least in the D1 antibody, the light 
chain CDR-loops are responsible for binding the flat β-sheet region on the allergen 
surface.  
 
 
4.2.5 SIGNIFICANCE TO ALLERGEN IMMUNOTHERAPY 
 
Allergen-specific immunotherapy has been used for the treatment of allergic diseases 
for almost a century. The method is based on controlled exposure to a sensitizing 
allergen that gradually modulates the immune system out of the IgE-mediated 
response. The mechanisms of immunotherapy are complicated, including several 
changes in T cell and B cell response and in the expression levels of different antibody 
classes.10 The changes involve a strong increase in the serum IgG concentration72,73 and 
the enhancement of the blocking activity of IgG antibodies.74 It has been proposed that 
the allergen-specific IgG antibodies are able to compete with IgE for allergen binding 
and inhibit the allergen-induced mast cell and basophils degranulation, and that they 
may prevent the IgE-facilitated presentation of allergens to T cells.10,75  
 
Recombinant allergens have several advantages over the conventionally used crude 
allergen extracts, which are prepared from natural allergen sources and usually contain 
a diverse amount of allergenic and non-allergenic proteins.76 While wild-type 
recombinant allergens have structural and immunological properties similar to natural 
allergens, further genetic engineering of allergen molecules has been used to produce 
modified allergen derivatives.77 Modified allergens with a reduced IgE binding 
capacity (i.e. hypoallergens) are considered safer and more efficient molecules for 
immunotherapy. Allergen derivatives used in immunotherapy should not induce severe 
IgE-mediated side effects and they have to be well tolerated. Meanwhile, the treatment 
has to be successful and quickly offer long-term protection with few doses.78  
 
The solved immunocomplex structure gave new information about the IgE antibody-
allergen interactions. The finding that the IgE antibodies seem to prefer different 
binding sites of an allergen than IgG antibodies is expected to be valuable in designing 
novel hypoallergens for allergen-specific immunotherapy. If the three-dimensional 
structure of an allergen is known, the potential IgE epitopes may be identified on the 
surface of an allergen and the binding strength of IgE to the allergen could be 
decreased by modifying the selected amino acid residues.  
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4.3 THE ANTI-TESTOSTERONE FAB FRAGMENT 5F2IV 
 
The space group P1 contained two 5F2 Fab fragments in the asymmetric unit. The 
high-resolution data of 1.5 Å enabled a clear structure determination. Based on electron 
density, the N-terminal glutamic acid of the heavy chain was displaced with the cyclic 
pyroglutamic acid. High flexibility was noticed in the constant domain loop between 
the residues Ser136H and Gly142H. The loop is frequently disordered in antibody 
structures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The overall structure of the 5F2 Fab in complex with testosterone. The 5F2 Fab 
fragment is presented as a cartoon model (a) and a surface model (b). Testosterone is shown as 
a gray stick model.  
 
 
The overall shape of an antigen binding site of an antibody tends to correlate with the 
type of the antigen.79 Small molecule binding antibodies frequently have long L1 and 
H2 loops, which create a concave geometry on the surface of the variable domains.80,81 
Although 5F2 Fab has long CDR-L1 (14 residues) and CDR-H2 (17 residues), the 
loops are folded into conformations that create a flat rather than concave antigen 
binding site (Figure 10a). The CDR-L1 forms a distorted helix, which is a typical 
conformation for canonical class 2 loops of a lambda chain. CDR-H2 belongs to class 
3 where the apex of the loop is bent toward the surface of the antibody. Whereas the 
hapten binding antibodies favor short CDR-H3 loops (average length 8-9 residues81), 
the CDR-H3 of 5F2 Fab includes 13 amino acid residues. However, the length of the 
loop is not uncommon for human antibodies.81 The amino acid composition of CDR-
H3 with the high abundance of aromatic residues corresponds well with the typical 
CDR-H3 loops. In the tip of the loop, two adjacent hydrophobic residues Leu102H and 
Trp103H create a hydrophobic patch on the antibody surface.  
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4.3.1 THE TESTOSTERONE BINDING SITE 
 
The solved structure shows that testosterone is almost completely buried in the deep 
binding pocket of 5F2 Fab. Upon binding, 88% (402 Å2) of the solvent accessible 
surface of testosterone (457 Å2) buries. The interface area of the antibody is 233 Å2, 
where the heavy chain contribution (84% of the buried surface) is substantially higher 
than the light chain contribution (16% of the buried surface). The D-ring of the 
testosterone is oriented toward the bottom of the binding pocket, which is analogous 
with the conjugation position to the carrier protein. The interactions between the 
antibody and the hapten are mainly hydrophobic and aromatic amino acid residues 
occupy a central role when binding the testosterone (Figure 11). The antibody binds the 
hapten principally through CDR-L3, CDR-H2 and CDR-H3 loops. The light chain 
CDR-loops L1 and L2 and the heavy chain CDR-H1 are not in contact with the hapten. 
These CDRs are not in the centre of the binding site and are usually in contact only 
with large antigens.79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. A stereo view of the testosterone binding site of the 5F2 Fab. The single hydrogen 
bond between the 5F2 Fab and the testosterone is shown as a broken black line. 
 
 
In total, 8 residues from the heavy chain and 2 residues from the light chain of 5F2 Fab 
interact with testosterone. The α-side of the steroid skeleton packs against two 
aromatic residues (Tyr100L and Tyr107H) and the β-side with two methyl groups is 
directed against the heavy chain of the antibody. Trp47H and Tyr105 are at opposite 
sides of the pocket, binding the testosterone in a perpendicular alignment with respect 
to the side-chains of the amino acid residues. Tyr59H on the solvent exposed surface of 
the antibody and the other light chain residue Pro99L interact with the A-ring and the 
B-ring of the testosterone. Three residues from CDR-H3 loop (Asp99H, Gly108H and 
Met109H) form the bottom of the binding pocket. The single hydrogen bond is formed 
between the 17-hydroxyl group of the testosterone and the side-chain of Asp99H. 
Buried water molecules were not detected inside the binding pocket of 5F2 Fab.  
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4.3.2 STEROID BINDING ANTIBODIES 
 
Steroids are small hydrophobic molecules, which are structurally closely related to 
each other. Since they are important compounds for diagnostics and therapeutic 
purposes, several antibodies have been generated against steroid molecules. The crystal 
structures of antibodies that specifically bind the major female sex hormones 
estrogen82,83 and progesterone84, male sex hormone testosterone37,85, digoxin86,87 and 
steroid glucuronides88, have been determined by X-ray crystallography. The orientation 
of the steroid molecule in the binding site, the number of hydrogen bonds between the 
antibody and the hapten and the heavy and light chain contribution to hapten binding 
vary among the antibody-steroid complexes. Common to all these structures is the 
hydrophobic binding site with its high abundance of aromatic amino acid residues and 
high shape complementarity between the antibody and the hapten. Previously, the 
crystal structure of an in vitro affinity and specificity matured Fab fragment (Fab 77) 
from a mouse monoclonal antibody89 was determined in free form and in complex with 
testosterone.37 The comparison of free and hapten-bound structures showed that Fab 77 
undergoes conformational changes when it binds testosterone. Since the attempts to 
crystallize 5F2 Fab without the hapten were not successful, a free form structure is not 
available for the detection of possible hapten-induced conformational changes in 5F2 
Fab.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Binding of testosterone to 5F2 Fab (a) and to 77 Fab (b). 
 
The sequence identity between 5F2 Fab and 77 Fab is lower for the light chain (44%) 
than for the heavy chain (71%). In both the 5F2 Fab and 77 Fab structures, testosterone 
is bound to the deep and hydrophobic pocket lined by the side-chains of aromatic 
amino acid residues. In the Fab 77-testosterone complex, the buried surface area of the 
hapten (92%) and the interface area of the antibody (234 Å2) are similar to the 5F2 Fab 
complex structure. The light chain of Fab 77 contributes more to hapten binding (38% 
of the total buried surface area) than the light chain of 5F2 Fab. Fab 77 binds 
testosterone in a sandwich between the side-chains of Trp47H and Tyr102H. The 
corresponding aromatic amino acid residues are found in the binding site of 5F2, but 
the relative orientation of testosterone is different between these two Fab fragments 
(Figure 12). Compared with the Fab 77-testosterone structure, the hapten is turned 
almost 90 degrees in the 5F2 Fab-testosterone complex. The different orientation of the 
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bound hapten molecule seems to result from Tyr100L and Tyr107H, which occur in the 
binding site of 5F2 Fab and interact with the α-side of the testosterone. Besides the 
direct hydrogen bond between the 17-hydroxyl group of the testosterone, a buried 
water molecule in the binding site of Fab 77 makes possible the indirect hydrogen 
bonding between the D-ring hydroxyl of testosterone and the main-chain of Ala33H 
and the side-chain of Ser35H. Thus, the closer fit between the testosterone and 
antibody, as well as the hydrogen bond interactions, are likely responsible for the 
nanomolar binding affinity of Fab 77 (Kd = 3 × 10-10 M), whereas the binding affinity 
of 5F2 Fab to testosterone is ~ 10-7 M.  
 
 
4.4 THE ANTI-TETRAHYDROCANNABINOL FAB FRAGMENT T3V 
 
The crystal structures of a T3 Fab in free form and in complex with 
tetrahydrocannabinol were solved at 1.9 Å and 2.0 Å resolution, respectively. The 
asymmetric unit of both forms contained one T3 Fab fragment. The electron density 
maps of the structures were of good quality and easy to interpret, with the exception of 
the flexible loops in the heavy chain regions of Ala134H-Met139H and Pro188H-
Val197H. CDR-loops were well ordered in both the free and the complex structures. 
Three CDR-loops of the light chain and the heavy chain CDR-loops H1 and H2 could 
be classified into the known canonical structure classes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The overall structure of the T3 Fab-tetrahydrocannabinol complex. The T3 Fab 
fragment is shown as a cartoon model (a) and a surface model (b), THC is in gray. 
 
Due to the length and the amino acid compositions of the CDR-loops, T3 Fab does not 
represent a typical hapten binding antibody. All six CDR-loops are relatively short, and 
thereby the surface of the antigen binding site is rather planar (Figure 13a). The amino 
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acid sequences within CDR-regions, especially within the H3-loop, are also fairly 
unusual. A typical CDR-H3 region is often rich in tyrosine, glycine and serine, rather 
than in hydrophobic residues with small side-chains, such as isoleucine and valine.90 
The CDR-H3 of T3 Fab does not contain any aromatic residues, but the loop is mainly 
constructed from aliphatic amino acid residues. 
 
 
4.4.1 THE TETRAHYDROCANNABINOL BINDING SITE 
 
The T3 Fab binds the tetrahydrocannabinol into a narrow hydrophobic cavity, which is 
located between the variable domains of the heavy chain and the light chain. In the 
complex structure, 469 Å2 (84%) of the total solvent accessible surface of THC (557 
Å2) is buried. The n-pentyl side-chain of THC, which is attached to the C3 carbon of 
the phenolic ring, buries deep into the interface area of the variable domains, whereas 
the C10 monoterpene part of the hapten is partially exposed to the solvent (Figure 13a, 
13b). The long hydrocarbon tail of the hapten molecule is able to reach four framework 
residues, which are highly conserved in the antibody structure.91 This is possible 
because the T3 Fab has a glycine near the C-terminus of the CDR-H3 loop. The 
position is often occupied by a bulky amino acid residue, which blocks the entry to the 
interior of an antibody. 249 Å2 of the solvent accessible surface of the antibody is 
buried in an antibody-antigen interface, and the heavy chain contribution on the buried 
surface area is 78%. All CDR-loops of the heavy chain and the CDR-3 loop of the light 
chain, together with five amino acids from the framework region interact with the 
hapten.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. The binding of tetrahydrocannabinol to T3 Fab, shown in stereo. Hydrogen bonds 
are shown as broken black lines. 
 
The binding site of the T3 Fab is mainly formed from aliphatic amino acid residues 
(Figure 14). The T3 Fab binds the n-pentyl side-chain of THC mainly through residues 
from CDR-H1 (Val35H) and CDR-H3 (Gly98H, Val102H, Ala103H, Gly104H) 
regions. Val33H and Val35H from CDR-H1, Gly98H and Val102H from CDR-H3, 
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together with Leu97L from CDR-L3 surround the phenolic ring of THC and create a 
hydrophobic batch around the aromatic ring. The rest of the binding interactions are 
directed towards the monoterpene moiety of the THC. The aromatic amino acid 
residues, Trp47H from the framework region and Tyr58H from CDR-H2, form an edge 
for the binding site. Ile95L is located near the solvent exposed surface of the antibody 
and makes contacts with the methyl groups of THC. The two polar groups of hapten 
are hydrogen-bonded with an antibody. The ether oxygen of the heterocyclic ring of 
THC forms a hydrogen bond with the Ser50H from CDR-H2. The second hydrogen 
bond is formed between the aromatic hydroxyl group of THC and the main-chain 
oxygen of Thr99H. Besides the four water molecules, which are displaced by THC in 
the complex structure, the electron density maps did not reveal other ordered water 
molecules or unexplained density inside the deep binding pocket of the free T3 Fab 
structure.  
 
4.4.2 HAPTEN-INDUCED CONFORMATIONAL CHANGES 
 
The comparison between the free form and complex structure shows that the T3 Fab 
does not undergo any large conformational rearrangements upon hapten binding. The 
calculated elbow angles are 156° and 157° for the free and the hapten-bound structures, 
respectively. The rmsd values between the Cα atoms of the free and the complex 
structures are 0.27 Å for the variable domain and 0.42 Å for the constant domain, 
which also indicate only subtle differences between the structures. Although the main-
chain is highly similar in both structures, some minor changes were observed in the 
side-chain conformations of amino acid residues. Small adjustments of the side-chain 
conformations of Ile95L, Leu97L, and Val33H slightly expanded the binding cavity 
and improved the fit between the THC and T3 Fab (Figure 15a, 15b).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The hapten-induced conformational changes. Binding site of T3 Fab in free form (a) 
and in complex structure (b) shown as surface models. c) Conformations of four amino acids 
near the binding site of T3 Fab. The free form structure is shown in magenta and the complex 
structure is in gray. 
 
Four residues (Thr28H, Asn30H, Asn31H, Arg53H) on the solvent exposed surface of 
the T3 Fab appear to have additional conformations in the complex structure. Two 
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favorable side-chain conformations were refined for each of these amino acids. One of 
these two conformations was observed in the free T3 Fab structure, with the exception 
of Arg53H, which occupies a distinct side-chain conformation (Figure 15c). These 
amino acids are not in contact with the bound hapten molecule, but they may influence 
the recognition mechanism of the secondary antibody.  
 
 
4.4.3 THE BINDING OF A PSYCHOACTIVE CANNABINOID TO AN 
ANTIBODY 
 
Tetrahydrocannabinol is a hydrophobic terpenophenolic compound, whose crystal 
structure has not been previously characterized by X-ray crystallography. The 
conformation of the Δ9-THC skeleton has been established by solving the crystal 
structures of the psychotropically inactive Δ9-tetrahydrocannabinol acid B92 and the 
moderately active 8β-hydroxy-Δ9-tetrahydrocannabinol.93 The stereochemistry of the 
THC in the binding site of the T3 Fab presents the natural active trans (6aR, 10aR) 
isomer conformation. As with the two previously determined cannabinoids, THC 
occurs in a bent conformation in the complex structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. a, b) The Fo-Fc omit map for the bound THC molecule contoured at 2.5 σ. b) The n-
pentyl side-chain of THC adopts both the anti and the gauche conformations in the binding site 
of T3 Fab. The gauche conformation is shown in orange. 
 
 
Both the cyclohexene ring and the phenol ring of THC occur in a half-chair 
conformation. The cyclohexene ring and the n-pentyl side-chain are located on the 
opposite sides of the planar phenol group (Figure 16a). The binding site of the T3 Fab 
is narrow, but the terminal methyl group of the side-chain of THC is still capable of 
rotating around the single carbon-carbon bond. Based on the electron density maps, the 
n-pentyl chain was found to occur in both the fully extended all-anti conformation and 
the gauche-conformation with respect to the C4´-C5´ bond (Figure 16b). 
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5 CONCLUSIONS 
 
In order to understand the molecular basis for the antibody specificity and binding 
affinity, the crystal structures of three different antibody-antigen complexes were 
determined by X-ray crystallography. The crystal structures of the IgE antibody-
allergen complex D1/BLG, the anti-testosterone Fab fragment 5F2 and the anti-
tetrahydrocannabinol Fab fragment T3 allowed the detailed identification of antibody-
antigen interactions and increased the knowledge of the recognition mechanisms of the 
antibodies. The solved structures are also expected to facilitate the design of specific 
modifications that could enhance the binding properties of the antibodies.  
 
The three-dimensional structure of the complex between the IgE Fab fragment D1 and 
the dimeric bovine beta-lactoglobulin allergen was solved at 2.8 Å resolution. This was 
the first structure of the IgE antibody-allergen immunocomplex and revealed the 
complete IgE epitope of an allergen, which was found to differ from common IgG 
epitopes of protein antigens. The findings that IgE antibodies seem to prefer different 
binding sites than the common IgG antibodies and that the protein oligomerization may 
increase its allergenicity could lead to novel approaches to the treatment of allergy.  
 
The combination of polystyrene nanospheres and the streak-seeding method was found 
to be an efficient technique for producing well-ordered protein crystals. The 5F2 Fab-
testosterone crystals that were obtained using this novel optimization strategy 
diffracted the synchrotron radiation up to 1.5 Å resolution. However, the twinning that 
occurred in the 5F2 Fab crystal complicated the structure determination. The twinning 
was not detectable from diffraction images and was not suspected until the refinement 
of the structure proved to be difficult. Pseudomerohedral twinning, where a triclinic 
crystal mimics a monoclinic one, has not been previously reported for protein crystals, 
so the type of twinning in the 5F2 Fab crystal was therefore difficult to identify. The 
solved structure showed that the binding site of the 5F2 Fab to testosterone is a deep 
hydrophobic pocket, which is located between the variable domains of the antibody. 
The high contribution of the aromatic amino acid residues towards hapten binding and 
the good shape complementarity between the antibody and the hapten was comparable 
with previously determined antibody-steroid structures.  
 
The crystal structure of the anti-tetrahydrocannabinol binding Fab fragment T3 was 
solved in free form at 1.9 Å resolution and in complex with THC at 2.0 Å resolution. 
The combination of the nanospheres and the seeding substantially enhanced the quality 
of the T3 Fab-THC crystals. The binding mechanism of a psychoactive cannabinoid to 
protein had not been determined by X-ray crystallography before this study. The T3 
Fab was found to bind the hapten into a narrow and deep pocket. The analysis of the 
binding interactions proved that the T3 Fab binds the hydrophobic cannabinoid 
molecule mainly through aliphatic amino acid residues and that the highly conserved 
amino acids from the framework region of the T3 Fab also interact with the hapten. 
The comparison between the free and THC-bound structures showed that large 
conformational changes do not occur in the T3 Fab when it binds hapten.  
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